Regeneron Pharmaceuticals (NQ:REGN)

An early-stage liver disease therapy cut fat by 70% in just 12 weeks, signaling the genetics engine's potential to fuel growth beyond current blockbusters.

Topics Earnings

Regeneron: 3 Key Takeaways for Long-Term Investors ↗

October 31, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2026 Earnings Beat Driven by Dupixent Growth ↗

Topics Earnings

October 30, 2026

Via Chartmill

Topics Earnings

REGN Q3 deep dive: pipeline progress and core brands drive outperformance

October 31, 2026

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 36.3% year on year to $5.12 billion. I...

What happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 11.5% in the afternoon session after the company reported a 36% increase in third-qua...

S&P 500 Top Movers: Gainers and Losers in Today's US Session ↗

October 30, 2026

Via Chartmill

Topics Stocks

S&P 500 Top Movers: Gainers and Losers in Today's Session ↗

October 30, 2026

Via Chartmill

Topics Stocks

Regeneron (REGN) stock trades up, here is why

October 30, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) reported third-quarter 2026 revenue growth of 36% year over year to $5.1 billion, while non-GAAP diluted earnings per share rose 70% to $20.07. The company...

Topics Artificial Intelligence

What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Call ↗

October 30, 2026

Dupixent, EYLEA HD, and Libtayo hit record sales, fueling record earnings growth.

Topics ETFs Earnings

Regeneron (REGN) Q3 2026 Earnings Call Transcript ↗

October 30, 2026

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 2026, with revenue up 36.3% year on year to $5.12 billion....

Topics Earnings

S&P 500 Premarket Gainers and Losers on Oct. 30, 2026 ↗

October 30, 2026

Via Chartmill

Topics Stocks

Regeneron (NASDAQ:REGN) surprises with strong Q3 2026, stock soars

October 30, 2026

Biotech company Regeneron (NASDAQ:REGN) will be announcing earnings results tomorrow before market hours. Here’s what investors should know. Regeneron beat a...

What to expect from Regeneron’s (REGN) Q3 earnings

October 29, 2026

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on hi...

1 safe-and-steady stock with exciting potential and 2 facing headwinds

October 23, 2026

Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market ↗

October 19, 2026

Is this company the biggest dark horse in the chronic weight management space?

Regeneron's biggest growth driver still has plenty of fuel left in the tank.

Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share ↗

October 17, 2026

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the biotechnology industry, including Regeneron (NASDAQ:REGN) and...

Q2 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks

October 14, 2026

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 4% in the afternoon session after the biotechnology company expanded its immunology all...

Topics Artificial Intelligence

Top S&P500 movers in Wednesday's session ↗

October 14, 2026

Via Chartmill

Discover which S&P500 stocks are making waves on Monday. ↗

October 12, 2026

Via Chartmill

Why Regeneron (REGN) Stock Is Trading Lower Today

October 01, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases,...

Which S&P500 stocks are moving on Thursday? ↗

October 01, 2026

Via Chartmill

Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion ↗

October 01, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f...

Topics ETFs

Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment

September 30, 2026

The healthcare company will release its third-quarter results next month.

Topics Artificial Intelligence

Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30? ↗

September 28, 2026

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

1 Profitable Stock with Impressive Fundamentals and 2 That Underwhelm

September 28, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development...

Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts ↗

September 23, 2026

The past couple of years have been challenging for the company, but there is a light at the end of the tunnel.

Topics ETFs

Is Regeneron Stock a Bargain Below $800? ↗

September 22, 2026

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...

Topics Intellectual Property

1 S&P 500 Stock Worth Your Attention and 2 We Ignore

September 22, 2026

Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗

Topics Stocks

September 15, 2026

Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now.

Regeneron Pharmaceuticals (NASDAQ:REGN) outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global...

Topics Regulatory Compliance

Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum ↗

September 14, 2026